Adefovir dipivoxil nella terapia dell’epatite B cronica: profilo farmacologico clinico ed economico

Lorenzo Pradelli, Mario Eandi



Despite the fact that an effective vaccine against hepatitis B virus (HBV) has been available for over 30 years, the worldwide prevalence of this infection is still very high. Until recently, there were only two effective therapeutic options for chronic hepatitis B (CHB), interferon and lamivudine, but both are considered suboptimal therapies, for different reasons. Adefovir dipivoxil (ADV) is the oral prodrug of adefovir, an acyclic nucleotide analogue that demonstrated virological and clinical effectiveness against HBV in experimental and real world settings. In this paper the main pharmacological and clinical evidence of ADV in CHB is reviewed. Health care economics data on the direct costs of CHB in different countries are presented and potential economical consequences of its introduction in Italy are discussed.


Chronic hepatitis B (CHB); Adefovir dipivoxil (ADV); Health care economics

Full Text:



  • There are currently no refbacks.

© SEEd srl